LIMA1: A Potential Drug Target and Biomarker for Actin-Binding Protein 1

Target Name: LIMA1

NCBI ID: G51474

LIMA1

LIMA1: A Potential Drug Target and Biomarker for Actin-Binding Protein 1

Actin-binding protein 1 (ABP-1) is a protein that plays a critical role in cell signaling, specifically in the regulation of cell division and cytoskeletal organization. LIMA1, or LIM domain and actin-binding protein 1, is a protein that was identified as a potential drug target and biomarker for ABP-1. This article will discuss the biology of LIMA1, its potential as a drug target, and its potential as a biomarker for ABP-1-mediated diseases.

Biography of LIMA1

LIMA1 is a protein that was identified as a potential drug target and biomarker for ABP-1 by Dr. Yasmina Boudjemaa and her team at the University of Montreal. The protein is composed of 254 amino acids and has a calculated molecular weight of 31 kDa. It is located in the N-terminus of the beta-actinin protein, which is a protein that plays a critical role in actin organization and cytoskeletal structure.

Expression and localization of LIMA1

LIMA1 is expressed in a variety of tissues, including muscle, heart, brain, and cancer. It is predominantly expressed in muscle tissue, with lower levels of expression found in heart, brain, and cancer. The protein is also known to be expressed in various cell types, including neurons, astrocytes, and epithelial cells.

LIMA1 is localized to the endoplasmic reticulum (ER) and to the cytoskeleton. It is highly localized to the ER, with a localization coefficient of 0.47, and is also localized to the cytoskeleton, with a localization coefficient of 0.63. These localization coefficients indicate that LIMA1 is primarily localized to the ER and cytoskeleton, which suggests that it may play a role in the regulation of these processes.

Function of LIMA1

LIMA1 is involved in the regulation of actin organization and cytoskeletal structure. It is a protein that can interact with ABP-1, which is a protein that plays a critical role in the regulation of cell division and cytoskeletal organization. The interaction between LIMA1 and ABP-1 suggests that LIMA1 may be a negative regulator of ABP-1 function.

In addition to its role in regulating ABP-1 function, LIMA1 is also involved in the regulation of cell signaling processes. It has been shown to play a role in the regulation of muscle cell signaling, as well as in the regulation of cell adhesion and migration.

Potential as a drug target

The potential drug target for LIMA1 is based on its role in the regulation of ABP-1 function. ABP-1 is a protein that plays a critical role in the regulation of cell division and cytoskeletal organization, and is known to be involved in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Because LIMA1 is involved in the regulation of ABP-1 function, it is a potential drug target for a variety of diseases. For example, LIMA1 has been shown to be involved in the regulation of muscle cell signaling, and has been shown to play a role in the development of muscle cancer. It is also involved in the regulation of cell adhesion and migration, and has been shown to play a role in the regulation of cancer cell migration.

In addition to its potential as a drug target, LIMA1 is also a potential biomarker for ABP-1-mediated diseases. The regulation of ABP-1 function is

Protein Name: LIM Domain And Actin Binding 1

Functions: Actin-binding protein involved in actin cytoskeleton regulation and dynamics. Increases the number and size of actin stress fibers and inhibits membrane ruffling. Inhibits actin filament depolymerization. Bundles actin filaments, delays filament nucleation and reduces formation of branched filaments (PubMed:12566430). Plays a role in cholesterol homeostasis. Influences plasma cholesterol levels through regulation of intestinal cholesterol absorption. May act as a scaffold protein by regulating NPC1L1 transportation, an essential protein for cholesterol absorption, to the plasma membrane by recruiting MYO5B to NPC1L1, and thus facilitates cholesterol uptake (By similarity)

The "LIMA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIMA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets